Aurinia Pharmaceuticals Inc

AUPHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
17.23 USD
↘ 0.32 (1.82%)AT CLOSE (11:59 AM EDT)
17.20
↘ 0.03 (0.17%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
17.20
↘ 0.03 (0.17%)
🔴Market: CLOSED

Aurinia Pharmaceuticals Inc (AUPH) is currently trading at $17.23. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Buy" respectively. Notable factors include a robust Altman Z-Score, exceptional Return on Equity (52.5%), a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place AUPH at a fair price relative to peers.

Technical & fundamental data as of Jun 26, 2026.

Open?$17.53
High?$17.72
Low?$16.75
Prev. Close?$17.55
Volume?4.5M
Avg. Volume?1.5M
VWAP?$17.11
Rel. Volume?2.95x
Bid / Ask
Bid?$14.59 × 100
Ask?$19.65 × 100
Spread?$5.06
Midpoint?$17.12
Valuation & Ratios
Market Cap?2.2B
Shares Out?128.6M
Float?103.0M
Float %?79.2%
P/E Ratio?7.43
P/B Ratio?3.90
EPS?$2.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
128
Market Cap
2.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.auriniapharma.com
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
100
Momentum?
73
Short Sent.?
34
Piotroski F-Score?6/9Mixed
Altman Z-Score?8.88Safe
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?8.99%Elevated
Short Interest?9.3M
Days to Cover?7.7
Free Float103.0M
Avg Daily Volume1.2M
Settlement Date2026-06-15
Financial Health
Current Ratio?5.55Strong
Quick Ratio?5.01Strong
Cash Ratio?0.47Low
Debt/Equity?0.11Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
Peers
100
S&P
97
7.4CHEAP▾
P/B?
Peers
100
S&P
45
3.90FAIR▾
P/S?
Peers
100
S&P
15
7.43HIGH▾
P/FCF?
Peers
100
S&P
79
13.3CHEAP▾
EV/EBITDA?
Peers
100
S&P
37
17.2FAIR▾
EV/Sales?
Peers
100
S&P
18
7.51HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
91
52.5%STRONG▾
ROA?
Peers
50
S&P
97
41.2%STRONG▾
Cash Flow & Enterprise
FCF?$166.6M
Enterprise Value?$2.2B
Fundamentals ratios updated end of day
MarketsMoversWatchlist